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Phosphatidylinositol-3 kinase-related kinases (PIKKs)
comprise a family of protein kinases that respond to
various stresses, including DNA damage, blocks in DNA
replication, availability of nutrients and errors in mRNA
splicing. PIKKs are characterized by the presence of a
conserved kinase domain (KD), whose activity is regu-
lated by two C-terminal regions, referred to as PIKK-regu-
latory domain (PRD) and FRAP-ATM-TRRAP-C-terminal
(FATC), respectively. Here, we review functional and
structural data that implicate the PRD and FATC domains
in regulation of PIKK activity, drawing parallels to phos-
phatidylinositol-3 kinases (PI3K), lipid kinases that have
sequence similarity to PIKKs. The PI3K C-terminus, which
we propose to be equivalent to the PRD and FATC domains
of PIKKs, is in close proximity to the activation loop of the
KD, suggesting that in PIKKs, the PRD and FATC domains
may regulate kinase activity by targeting the activation
loop.
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Introduction
Phosphatidylinositol-3 kinase-related kinases (PIKKs) com-
prise a family of Ser/Thr-protein kinases with sequence
similarity to phosphatidylinositol-3 kinases (PI3Ks). PIKKs
are conserved in evolution and several homologues can be
found in many organisms starting from yeast (Keith and
Schreiber, 1995; Manning et al, 2002). In human beings, the
PIKK family includes six members: ataxia-telangiectasia
mutated (ATM), ataxia- and Rad3-related (ATR), DNA-dependent
protein kinase catalytic subunit (DNA-PKcs), mammalian
target of rapamycin (mTOR), suppressor of morphogenesis
in genitalia (SMG-1) and transformation/transcription
domain-associated protein (TRRAP). Several of these mem-
bers are linked to human diseases. Germline mutations
targeting ATM, ATR and DNA-PKcs lead to ataxia-telangiec-
tasia, Seckel syndrome and severe combined immunodeﬁ-
ciency, respectively (Savitsky et al, 1995; O’Driscoll et al,
2003; van der Burg et al, 2009). Further, somatic mutations
targeting ATM are frequent in lymphoma, colon cancer and
lung adenocarcinoma (Fang et al, 2003; Greenman et al, 2007;
Ding et al, 2008).
At the cellular level, PIKKs have diverse biological func-
tions. ATM, ATR and DNA-PKcs are involved in the response
to DNA damage: ATM and DNA-PKcs respond to DNA
double-strand breaks (DSBs) and ATR to DNA replication
blocks or other conditions that lead to formation of long
stretches of single-stranded DNA (Shiloh, 2003). mTOR is a
nutrient-regulated kinase that controls a wide variety of
pathways involved in metabolism and cell growth
(Wullschleger et al, 2006). SMG-1 is part of the mRNA
surveillance complex that regulates nonsense-mediated
mRNA decay (Yamashita et al, 2005). Finally, TRRAP func-
tions as part of a multiprotein co-activator complex posses-
sing histone acetyltranferase activity that is important for the
transcriptional activity of c-Myc and other transcription fac-
tors (McMahon et al, 2000). It should be noted that TRRAP,
unlike the other PIKKs, does not possess kinase activity,
because the amino acids required for such activity are absent
in its kinase-like domain (McMahon et al, 1998). Never-
theless, TRRAP has high sequence similarity with the other
PIKKs and is considered as a true member of this family.
At the protein level, four domains are conserved in PIKKs and
distinguish them from other protein kinases (Figure 1A). From
the N-terminus to the C-terminus, these are the FRAP-ATM-
TRRAP (FAT) domain, the kinase domain (KD), the PIKK-
regulatory domain (PRD) and the FAT-C-terminal (FATC) domain
(Keith and Schreiber, 1995; Bosotti et al, 2000; Mordes et al,
2008). The KD has low sequence similarity to classical eukar-
yotic protein kinases, which is why PIKKs are considered as
atypical protein kinases (Manning et al, 2002). In fact, the KDs of
PIKKs have higher sequence similarity to PI3Ks, lipid kinases
that phosphorylate the 3-hydroxyl group of phosphoinositides to
generate second messengers that induce cell proliferation
(Cantley, 2002). Owing to this sequence similarity, PI3Ks may
serve as a framework for understanding PIKK function.
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3067Mammalian PI3Ks are divided into three classes desig-
nated by roman numerals (Domin and Waterﬁeld, 1997).
Of interest to this review, class I enzymes consist of a
catalytic subunit, of which there are four isoforms and a
regulatory subunit. The catalytic subunits p110a,p 1 1 0 b and
p110d associate with the SH2-domain containing regulatory
subunit p85, whereas the catalytic subunit p110g associates
with the regulatory subunit p101, which interacts with G-
protein-coupled receptors (Carpenter et al, 1993; Stephens
et al, 1997). The gene encoding the p110a catalytic subunit is
mutated in many human cancers with the frequency of
mutation reaching 30% in colon and breast cancer
(Samuels et al, 2004; Vogt et al, 2007; Zhao and Vogt, 2008).
Regulation of PIKKs by the FAT, FATC
and PRD domains
As mentioned above, three domains, referred to as FAT, PRD
and FATC, are conserved in PIKKs, in addition to the KD
(Bosotti et al, 2000) (Figure 1A). These three domains
regulate the activity of the KD.
The FAT domain is just N-terminal to the KD. The three-
dimensional structure of a small part of the FAT domain
of mTOR has been determined and shows a domain consist-
ing entirely of four a-helices (Choi et al, 1996). In mTOR,
this part of the FAT domain, just N-terminal to the KD, is
referred to as the FKBP12-rapamycin-binding (FRB) domain,
because it binds the complex of the FKBP12 protein with
rapamycin (Stan et al, 1994; Chen et al, 1995). Sequence
analysis of PIKK family members suggests that the entire
FAT domain and even the entire N-terminus of these
proteins is a-helical (Perry and Kleckner, 2003). The sequence
analysis further predicts that the majority of these a-helices
adopt a tertiary structure similar to that of HEAT repeats
(so called, because they are present in Huntingtin, Elongation
factor 3, Alpha-regulatory subunit of protein phosphatase 2A
and TOR1). This prediction is supported by electron
microscopy-derived structures of human ATM, human DNA-
PKcs and yeast TOR1, which show that their N-termini form
a curved tubular-shaped domain similar to that adopted
by proteins containing HEAT repeats (Llorca et al, 2003;
Rivera-Calzada et al, 2005; Spagnolo et al, 2006; Adami
et al, 2007).
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Figure 1 Domain structure and alignment of PIKKs and PI3Ks. (A) Schematic presentation of the known protein domains of selected PIKKs
and PI3Ks. All the kinases shown are human, except for mTOR, which is of rat origin, and Mec1 and Tor1, which are S. cerevisiae proteins.
PI3Ka and PI3Kg refer to the PI3K catalytic subunits p110a and p110g, respectively. The abbreviations of the domains are mentioned in the text.
(B, C) Amino-acid alignment of the PRD (B) and FATC (C) domains of selected PIKKs to the C-terminal a-helices of the PI3K catalytic subunits
p110a and p110g. The boundaries of helices aK11, aK12 and aK13 of p110g are shown below its sequence. Regions of homology are coloured
green (four or more identical residues at that position) and yellow (ﬁve or more similar residues at that position). Residues, whose substitution
decreases kinase activity, are coloured red; residues, whose substitution does not affect or enhances kinase activity, are coloured blue; residues
of ATM targeted naturally by mutations in ataxia-telangiectasia patients are coloured orange. Residue numbers for each protein are indicated in
parentheses.
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predicted HEAT repeats N-terminal to the KD regulate PIKK
kinase activity. First, the FRB domain of mTOR is bound by
the complex of rapamycin with FKBP12 and rapamycin is a
potent inhibitor of mTOR kinase activity (Stan et al, 1994;
Chen et al, 1995; Choi et al, 1996). One could speculate that
rapamycin competes for binding of activators to mTOR.
Second, Nbs1, a subunit of a tripartite protein complex that
recognizes DNA DSBs, binds to the N-terminus of ATM and
enhances its kinase activity (You et al, 2005). Finally, Ku70/
Ku80 heterodimers and DNA induce conformational changes
in the FAT domain of DNA-PKcs and enhance its kinase
activity (Spagnolo et al, 2006).
The FATC domain comprises the very C-terminus of PIKKs.
It is a small, highly conserved domain of about 30 amino
acids in length (Bosotti et al, 2000). The high degree of
sequence conservation makes it possible to substitute FATC
domains among certain PIKK family members and maintain
functionality. For example, the FATC domain of ATM can be
replaced by the FATC domains of ATR, TRRAP or DNA-PKcs
without loss of function (Jiang et al, 2006). However, when
the FATC domains of ATR or mTOR are replaced by that of
ATM, then function is lost (Takahashi et al, 2000; Mordes
et al, 2008).
The three-dimensional structure of the FATC domain of
Saccharomyces cerevisiae Tor1 has been determined by NMR
spectroscopy and is comprised of an a-helix followed by a
sharp turn. The turn is stabilized by a disulphide bond
formed between Cys2460 in the helix and Cys2467 in the
sequence C-terminal to the helix (Dames et al, 2005). The
FATC domain has also been interpreted to have been visua-
lized in low resolution electron microscopy structures of
yeast Tor1 and human DNA-PKcs; in these structures, it is
shown to protrude from the KD (Rivera-Calzada et al, 2005;
Spagnolo et al, 2006; Adami et al, 2007).
Several studies indicate that the FATC domain of PIKKs is
critical for kinase activity and is very sensitive to muta-
genesis. Deletion of even one residue from the C-terminus
of mTOR abolishes kinase activity (Peterson et al, 2000) and
various single and double amino-acid substitutions in the
FATC domain of several PIKKs reduce kinase activity drama-
tically (Takahashi et al, 2000; Nakada et al, 2005; Sun et al,
2005; Morita et al, 2007). The mutagenesis experiments
suggest that the conserved hydrophobic amino acids in the
FATC domain are critical for function (Figure 1C). For exam-
ple, in SMG-1, substitution of Leu3646 with alanine reduces
kinase activity by 490% and substitution of Trp3653 with
phenylalanine, a substitution that has only a small effect on
hydrophobicity, reduces kinase activity by 50% (Morita et al,
2007). A naturally occurring mutation in a patient with
ataxia-telangiectasia also targets the FATC domain of ATM
(Cavalieri et al, 2006).
The current model for FATC domain function proposes that
these domains mediate protein–protein interactions. For ex-
ample, the histone acetyltransferase Tip60 binds to the FATC
domains of ATM and DNA-PKcs and enhances their kinase
activity in response to DNA damage. For ATM, it has further
been shown that the mechanism involves direct acetylation
of its PRD domain by Tip60 (Sun et al, 2005, 2007; Jiang et al,
2006). A second example involves Mec1, the budding yeast
homologue of human ATR, whose FATC domain interacts
with Rfa1 (Nakada et al, 2005). Rfa1 is the largest subunit of
the yeast replication protein A (RPA) complex, a single-
stranded DNA-binding protein that localizes to sites of DNA
damage and stalled replication forks. The interaction of the
FATC domain of Mec1 with Rfa1 not only facilitates recruit-
ment of Mec1 to sites of DNA damage, but may also have
other functional consequences, such as regulation of the
kinase activity of Mec1 (Nakada et al, 2005). Rfa1 also
binds Ddc2, a protein that associates tightly with Mec1; the
Rfa1–Ddc2 interaction is conserved in human cells and seems
to also be responsible for recruitment of ATR and Mec1 to
sites of DNA damage and replication stress (Zou and Elledge,
2003; Ball et al, 2005).
The PRD was recently deﬁned as the region between the
kinase and FATC domains (Mordes et al, 2008). This region is
not very highly conserved between different PIKKs and, with
the exception of SMG-1, its length varies between 16 and 82
amino acids. Deletion of the entire PRD abolishes kinase
activity, but speciﬁc small deletions within the PRD, for
example, of residues 2430–2450 of rat mTOR or of residues
2569–2576 of human ATR do not compromise or even, in the
case of mTOR, enhance kinase activity (Sekulic et al, 2000;
Mordes et al, 2008). These small deletions correspond to the
N-terminal half of the PRD, which shows almost no sequence
conservation among PIKKs (Figure 1B). A monoclonal anti-
body raised against amino-acids 2433–2450 of rat mTOR also
enhances kinase activity (Brunn et al, 1997), mimicking the
effect of deleting these residues.
The more highly conserved C-terminal half of the PRD
(Figure 1B) appears to be the site of posttranslational mod-
iﬁcations or protein–protein interactions that enhance PIKK
kinase activity. In ATM, Lys3016 becomes acetylated by Tip60
and substitution of this residue with arginine does not affect
basal ATM kinase activity, but suppresses the activation of
ATM by DNA damaging agents (Sun et al, 2005, 2007).
Further, Arg3008 is substituted by cysteine in an ataxia-
telangiectasia patient (Li and Swift, 2000). In ATR, the PRD
interacts with the activation domain of topoisomerase II-
binding protein 1 (TopBP1); this is the domain of TopBP1
that enhances ATR kinase activity in vitro and in vivo
(Kumagai et al, 2006; Mordes et al, 2008). Speciﬁc amino-
acid substitutions targeting the PRD of ATR, such as of
Lys2589 with glutamic acid, compromise the interaction of
ATR with TopBP1, the induction of TopBP1-dependent kinase
activity and the checkpoint function of ATR, but do not affect
basal kinase activity (Mordes et al, 2008). In DNA-PKcs,
charge-reversal amino-acid substitutions targeting the PRD
also compromise its kinase activity (Mordes et al, 2008).
Finally, in rat mTOR, two residues within its PRD, Thr2446
and Ser2448, are phosphorylated by S6K1 in response to
mitogens and nutrients (Chiang and Abraham, 2005; Holz
and Blenis, 2005), although the function, if any, of these
phosphorylations on mTOR kinase activity is not well
established (Sekulic et al, 2000).
Regulation of PI3Ks: structure–function
relationship
No atomic resolution structures of the KDs of any of the
PIKKs have been determined. However, the three-dimen-
sional structures of the PI3K catalytic subunits p110a and
p110g have been determined alone or in complex with
different co-regulators. The ﬁrst solved structure was that of
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1999). This was followed by the structure of the same
fragment of p110g in complex with Ras (Pacold et al, 2000)
and then by the structure of full-length p110a in complex with
a fragment of the p85a-regulatory subunit (Huang et al,
2007). The structure of the N-terminally truncated p110g
catalytic subunits show four domains: a Ras-binding domain
(RBD), a C2 domain, a helical domain and the KD, whereas
the structure of the full-length p110a subunit also shows the
adaptor-binding domain (ABD) (Figure 1A). The three-di-
mensional structures of the helical and KDs are of greatest
interest from the PIKK perspective and, therefore, only these
will be described here (Figure 2).
The helical domains of p110a and p110g adopt very similar
structures consisting of pairs of anti-parallel a-helices. These
pairs form a stack with an arrangement very similar to that
present in HEAT repeats. Thus, even though the amino-acid
sequences of the PI3K catalytic subunits do not match the
motif for HEAT repeats, their three-dimensional structure
reveals signiﬁcant structural similarity to that of HEAT re-
peats (Walker et al, 1999). This then raises the possibility that
the FAT domains of the PIKKs, which have been predicted to
be HEAT repeats (Perry and Kleckner, 2003), adopt a three-
dimensional structure very similar to that of the helical
domains of p110a and p110g.
In PI3Ks, the helical domains serve as a scaffold to which
the other domains of the catalytic subunit are attached
(Figure 2). Three residues towards the N-terminus of the
helical domain of p110a, Glu542, Glu545 and Gln546 are
frequently targeted by mutations found in human cancers
(Samuels et al, 2004; Gymnopoulos et al, 2007). The tumour-
associated mutations at these positions are charge-reversal
mutations (glutamic acid to lysine) that enhance kinase
activity and make p110a insensitive to regulation by p85a
(Ikenoue et al, 2005; Isakoff et al, 2005; Kang et al, 2005;
Samuels et al, 2005; Zhao et al, 2005; Bader et al, 2006;
Gymnopoulos et al, 2007; Zhao and Vogt, 2008). In the
wild-type p110a/p85a complex, the N-terminal SH2 (nSH2)
domain of p85a binds to the negatively charged N-terminus
of the helical domain of p110a; this interaction, which brings
the nSH2 domain close to the KD, suppresses kinase activity
(Yu et al, 1998a,b; Miled et al, 2007). Under growth-stimulat-
ing conditions, negatively charged tyrosine-phosphorylated
receptors bind to the nSH2 domain of p85a and prevent it
from interacting with the p110a subunit, thus relieving its
inhibitory effect on the kinase. According to this model, the
tumour-associated mutations have a similar effect, displacing
the nSH2 domain from the p110a subunit (Miled et al, 2007).
The KDs of p110a and p110g adopt very similar three-
dimensional structures to one another and interact exten-
sively with the helical domain (Figure 2). Despite the poor
sequence similarity between the KDs of PI3Ks and classical
protein kinases, at the three-dimensional level there are
considerable similarities. In both families, the KDs have
N- and C-terminal lobes and conserved secondary structure
elements, especially around the ATP-binding site. An inter-
esting feature in the PI3K structures is the activation loop,
a signiﬁcant part of which is disordered and, therefore, not
visible in the electron density maps. However, the N- and
C-terminal ends of the activation loop are visible and are
surrounded from three sides by the three C-terminal a-helices
of the KD. These helices are better resolved in the structure of
p110g bound to ATP. We will refer to them as helices aK11,
aK12 and aK13 (Figure 2), so that we have the same
terminology for both p110a and p110g, although in p110g
they have been referred to as helices aK10, aK11 and aK12,
respectively (Walker et al, 1999; Pacold et al, 2000). These
three helices are on the same plane and form the three sides
of an imaginary rectangle. The N- and C-terminal ends of the
activation loop are within this rectangle. The most C-terminal
helix, aK13, is characterized by the presence of conserved
residues with large hydrophobic side chains, such as Trp1080,
Trp1086 and Phe1087. The side chains of these residues face
towards the hydrophobic core of the KD and are, therefore,
likely to stabilize the position of helix aK13 against the rest of
the KD. Interestingly, in the p110a structure, the C-terminal
a-helix is disordered and, apparently, not in contact with the
rest of the KD (Huang et al, 2007). This raises the possibility
that the C-terminal helix of the KD of PI3Ks is conformation-
ally ﬂexible, perhaps adopting different conformations in the
active and inactive states.
Tumour-associated mutations targeting residues in the KD
of p110a are quite frequent and, interestingly, map to the
C-terminal half of helix aK12 (Samuels et al, 2004;
Gymnopoulos et al, 2007). The targeted residues are
His1047, which is substituted with arginine, leucine or tyr-
osine, and Met1043, which is substituted with isoleucine or
E542 E545
Q546
ATP
H47
M43
W66
W80
F87
W70
W86
αK11
αK12
HEL
KD
TOR1
PI3Kα
PI3Kγ
αK13
F69
Figure 2 Superimposition of the FATC domain of S. cerevisiae Tor1
(PDB ﬁle 1w1n) and of helices aK12 and aK13 of the PI3K catalytic
subunit p110g (PDB ﬁle 1e8x) on the three-dimensional structure of
the helical and kinase domains (KDs) of the PI3K catalytic subunit
p110a (PDB ﬁle 2rd0), according to the alignment shown in
Figure 1B. The p110a helical (HEL) and KDs are coloured green
and blue, respectively. The activation loop is coloured red; the red
spheres mark the boundaries of the part of the activation loop,
whose structure was not determined. The ATP, from the p110g
structure, is coloured orange. Helices aK11 and aK12 of p110a are
coloured purple and bright yellow, respectively. Helix aK13 of p110a
was not resolved in the electron density map and is not shown.
Helices aK12 and aK13 of p110g are coloured dark yellow, as are the
side chains of the p110g residues Trp1080 (W80), Trp1086 (W86)
and Phe1087 (F87). The FATC domain of Tor1 is coloured light
purple, as are the side chains of its residues Trp2466 (W66),
Phe2469 (F69) and Trp2470 (W70). Note that residues 2465–2470
of Tor1 were modelled according to the p110g structure, as described
in the text. Residues of p110a targeted by cancer-associated muta-
tions map to the N-terminus of the helical domain (E542, Glu542;
E545, Glu545; Q546, Gln546) and to helix aK12 (M43, Met1043;
H47, His1047). PI3Ka and PI3Kg refer to the PI3K catalytic subunits
p110a and p110g, respectively.
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KD, their substitution may affect the interaction of helix aK12
and, by consequence, of helix aK13 with the rest of the KD.
The proximity of helices aK12 and aK13 to the activation loop
suggests an effect on the conformation of the activation loop.
Comparison of the structures of p110g on its own or in
complex with Ras shows an interaction of Ras with the
C-terminal lobe of the KD and modest conformational
changes that also affect helices aK12 and aK13 (Pacold
et al, 2000). Exactly how these conformational changes
enhance kinase activity is not clear, especially as the activa-
tion loop is disordered in both structures. However, it is of
interest that the tumour-associated mutations that map to
helix aK12 enhance kinase activity and render PI3K insensi-
tive to regulation by Ras, whereas preserving regulation by
p85a (Ikenoue et al, 2005; Isakoff et al, 2005; Kang et al,
2005; Samuels et al, 2005; Zhao et al, 2005; Bader et al, 2006;
Gymnopoulos et al, 2007; Zhao and Vogt, 2008).
A model for regulation of the PIKKs
To gain more insights into the regulation of PIKKs, we
considered the possibility that the three-dimensional struc-
ture of the helical and KDs of the PI3K catalytic subunits is
similar to the structure of the FAT, kinase, PRD and FATC
domains of PIKKs. First, as mentioned above, the helical
domain of PI3Ks has a three-dimensional structure similar
to that of HEAT repeats, and the amino-acid sequence of the
FAT domain of PIKKs matches the HEAT repeat consensus
motif (Walker et al, 1999; Perry and Kleckner, 2003). One
may, therefore, predict that in PIKKs, the FAT domain adopts
a conformation similar to that of the helical domain of PI3Ks.
Further, the KDs of PIKKs and PI3Ks have signiﬁcant
sequence similarity and, therefore, are likely to adopt similar
three-dimensional structures. Finally, the three C-terminal
a-helices of the KD of p110g have sequence similarity to the
PRD and FATC domains of PIKKs: helix aK11 of p110g can be
aligned to the C-terminal half of the PRD domain, whereas
helices aK12 and aK13 can be aligned to the FATC domain
(Figure 1B and C). If indeed, the PRD and FATC domains of
PIKKs adopt a three-dimensional structure similar to that of
the C-terminal three a-helices of p110g, then they would be
physically close to the activation loop and, thus, ideally
placed to regulate kinase activity.
The only PIKK polypeptides, whose three-dimensional
structure has been determined at the atomic level, are the
FRB domain of mTor and the FATC domain of budding yeast
Tor1 (Choi et al, 1996; Dames et al, 2005). We wondered
whether we could superimpose the FATC domain of Tor1 on
the structure of the PI3K catalytic subunit on the basis of their
sequence alignment (Figure 1B). As mentioned above, the
FATC domain of Tor1 folds as an a-helix followed by a sharp
turn. The latter is stabilized by a disulphide bridge between
Cys2460 and Cys2467 (Dames et al, 2005). However, these
two cysteines are not conserved in other PIKKs and are
unlikely to form a disulphide bond in the reducing intracel-
lular environment. Therefore, we superimposed the a-helix of
Tor1 on helix aK12 of p110g, but then modelled the remaining
FATC residues according to the p110g structure. Doing so led
to the conserved C-terminal Tor1 residues Trp2466, Phe2469
and Trp2470 facing towards the KD, in a manner analogous to
the orientation of the p110g conserved residues Trp1080,
Trp1086 and Phe1087 (Figure 2).
The possibility that the FAT, kinase, PRD and FATC do-
mains of PIKKs adopt a similar three-dimensional structure to
the helical and KDs of PI3Ks provides some room for spec-
ulation on how PIKK kinase activity may be regulated. In
PI3Ks, activation requires two converging mechanisms
(Miled et al, 2007). The ﬁrst mechanism involves activated
Ras, whose binding to the RBD of PI3Ks induces conforma-
tional changes in the C-terminal lobe of the KD (Pacold et al,
2000). These conformational changes may facilitate enhance-
ment of the kinase activity by targeting the aK12 and aK13
helices, since amino-acid substitutions associated with can-
cer that target these helices enhance kinase activity and
render it insensitive to regulation by Ras. The second
mechanism involves the nSH2 domain of the p85a-regulatory
subunit. This SH2 domain binds to the helical domain when
PI3K is inactive, but is released from the helical domain when
a competing SH2-binding site becomes available in growth
factor-stimulated cells; these competing SH2-binding sites are
phosphorylated tyrosines of activated growth factor tyrosine
kinase receptors (Miled et al, 2007). The release of the SH2
domain from the helical domain and the activated
Ras-induced conformational changes may synergistically
impact on the conformation of the C-terminal helices aK11,
aK12 and aK13, which in turn may switch on kinase activity
by affecting the conformation of the PI3K activation loop.
Using the PI3K analogy, one can hypothesize that the PRD
and FATC domains of PIKKs integrate different signals leading
to activation of these kinases. For example, the activation
domain of TopBP1 binds to the PRD of ATR (Mordes et al,
2008), whereas RPA binds to its FATC domain (based on
evidence with the homologous yeast proteins, as described
above; Nakada et al, 2005). Together, these interactions may
switch on ATR kinase activity by synergistically affecting the
conformation of the activation loop. In the case of ATM,
binding of the MRN complex to its N-terminus (You et al,
2005) may affect the conformation of its FATC domain,
somewhat analogous to how Ras affects the conformation
of the C-terminal lobe of the PI3K KD, whereas Tip60 targets
the PRD for acetylation (Sun et al, 2005, 2007). Such a model,
whereby the PRD and FATC domains integrate different
signals, may help explain why activation of PIKKs is not
promiscuous.
Signiﬁcant progress has been made regarding our under-
standing of the regulation of PIKKs in the last few years, but
much more needs to be learnt. The determination of the
three-dimensional structure of a PIKK will establish whether
its PRD and FATC domains adopt a three-dimensional struc-
ture similar to that of the C-terminal a-helices of PI3Ks, as
proposed here, and, accordingly, to what extent we can use
insights from PI3Ks to understand PIKK function.
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